Abstract
After radical prostatectomy, 25% to 35% of patients develop progression of serum prostate-specific antigen (PSA). Positron emission tomography of radiolabelled prostate-specific membrane antigen ligands (PSMA-PET) is more sensitive and specific than conventional imaging for lesion detection. This trial-in-progress (NCT04557059) uses PSMA-PET-evaluated staging and outcomes to investigate adding apalutamide (a next-generation nonsteroidal androgen receptor antagonist) to radiotherapy (RT) and a luteinizing hormone-releasing hormone agonist (LHRHa) in patients with high-risk, PSMA-PET-positive hormone-sensitive prostate cancer, nonmetastatic on conventional imaging.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
